{
  "docId": "019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "docSlug": "03e126adc7ca1480",
  "documentTitle": "20250114 bayer handout jpm 2025",
  "authorId": "JPMorgan",
  "authorName": "Bayer",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 14,
  "pageCount": 18,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "case_study",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a process-flow structure to describe the clinical development status of a specific asset.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "process_diagram",
    "photo"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-9cdc5d048fe2/14",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.08,
        "y": 0.22
      },
      "kind": "callout",
      "text": "BEMDANEPROCEL in Parkinson's disease",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4de1862-cfee-4a70-aafb-4157769d916b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Bemdaneprocel is the first PSC-derived cell therapy with positive Phase I data in PD.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-2301-748f-910f-fcb036374d2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.68,
        "y": 0.22
      },
      "kind": "image",
      "text": "Neural network illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3886c8b7-1aac-4fb4-a32c-d3c874fa0c5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.68,
        "y": 0.65
      },
      "kind": "image",
      "text": "Neuron illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1bba441-f103-42e4-a49b-2e9851df2e4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.15,
        "y": 0.87
      },
      "kind": "list",
      "text": "Plan to initiate Phase III trial announced on Jan 13, 2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1be7b094-dcde-471e-aebf-e749451aac00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.5,
        "x": 0.08,
        "y": 0.68
      },
      "kind": "list",
      "text": "Favorable safety profile through 24-months post transplantation. Trends towards improvement or stability across motor, non-motor, and quality of life assessments indicate potential clinical benefit.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d2c0ae7-9268-4ee5-9b52-b35488bcfc9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.15,
        "y": 0.58
      },
      "kind": "list",
      "text": "Bemdaneprocel is the first PSC-derived cell therapy with positive Phase I data in PD.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "815f3be6-a000-4035-b7ac-6b4f6cc40305",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.08,
        "y": 0.35
      },
      "kind": "list",
      "text": "Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting more than 11 million people globally and ~1 million in the US. Current treatments do not replace lost dopaminergic neurons and lose efficacy over time, leading to motor complications.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fb440ee-4240-4d9f-835a-a5e7a8d94c2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.36,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1 PSC = pluripotent stem cells",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0ca135b-f58c-45a0-b981-2af915835cd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.08,
        "y": 0.08
      },
      "kind": "title",
      "text": "Accelerating Development of Promising Assets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de3a25f2-398f-4894-a1b6-0340705249c1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "f381b448-fcf0-4030-b26e-c9fd2c74d1c9",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The slides showcase the company's market-leading positions and innovation",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}